CTLA4 and myeloid sarcoma: This has significant implication for the development of novel treatments for autoimmune conditions including MS but also emphasises the need for caution with clinical use of CTLA-4 immune checkpoint inhibitors, particularly in those with a history of immune-mediated demyelination.